Erratum to: Clin Transl Oncol DOI 10.1007/s12094-012-0985-x
Unfortunately, the original publication contains two errors.
-
1.
Table 2 has been published incorrectly, the correct version is given below:
-
2.
Reference 9 is not correct, the reference should read as follows:
9. Motzer RJ, Escudier B, Tomczak P et al (2012) Axitinib vs sorafenib for advanced renal cell carcinoma: phase III overall survival results and analysis of prognostic factors. Ann Oncol 23(Suppl 9):IX262
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s12094-012-0985-x.
Rights and permissions
About this article
Cite this article
Afonso, F.J., Anido, U., Fernández-Calvo, O. et al. Erratum to: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor. Clin Transl Oncol 15, 499 (2013). https://doi.org/10.1007/s12094-013-1032-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-013-1032-2